D-Day For TBRA, Nicox Falls As FDA Rejects Vesneo, EXEL Awaits EMA Decision

Tobira Therapeutics Inc. (TBRA) is all set to hold a teleconference and webcast at 8:30 a.m. Eastern Time today (July 25) to discuss phase IIb results for Cenicriviroc in patients with non-alcoholic steatohepatitis and liver fibrosis. Will Cenicriviroc make a mark? We will have to wait for the results.

from RTT - Biotech http://ift.tt/2aESfKN
via IFTTT